A randomized controlled trial concludes that in patients with type 1 diabetes who receive multiple daily insulin injections, the use of CGM resulted in a significant decrease in HbA1c levels over 24 weeks compared to usual care. This evidence concerns the gene INS and type 1 diabetes mellitus.